INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX

Core Viewpoint - A class action lawsuit has been filed against Boston Scientific Corporation, alleging securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Boston Scientific and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until May 4, 2026, to request to be appointed as Lead Plaintiff if they purchased Boston Scientific securities during the Class Period [2]. Group 2: Financial Performance - On February 4, 2026, Boston Scientific reported lower-than-expected sales in its electrophysiology division and provided fiscal year 2026 guidance that fell short of analyst expectations [4]. - The company attributed its disappointing results and guidance to slower-than-expected market growth and increased competition [4]. - Following this news, Boston Scientific's stock price dropped by $16.12 per share, or 17.6%, closing at $75.50 per share on February 4, 2026 [4].